Clinico-pathological characteristics of p63 expression in B-cell lymphoma

Cancer Science

Volumn 97, Issue 10, 2006, Pages 1050-1055

  Fukushima, Noriyasu ^a   Satoh, Toshimi ^a   Sueoka, Naoko ^a   Sato, Akemi ^a   Ide, Masaru ^a   Hisatomi, Takashi ^a   Kuwahara, Nobuo ^a   Tomimasu, Rika ^a   Tsuneyoshi, Naoko ^a   Funai, Noriko ^a   Sano, Masayuki ^b   Tokunaga, Osamu ^a   Sueoka, Eisaburo ^a  

^a SAGA UNIVERSITY   (Japan)

^b Maeda Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN P21; PROTEIN P63; RITUXIMAB; STEROID; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLICULAR LYMPHOMA; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TRANSCRIPTION INITIATION;

ADULT; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; DNA-BINDING PROTEINS; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 33748297438     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00284.x     Document Type: Article

References (30)

1. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermalmorphogenesis. Nature 1999; 398: 708-13.
2. Yang A, Schweitzer R, Sun D et al. p63 is essential for regenerative proliferation in limb, craniofacial, and epithelial development. Nature 1999; 398: 714-8.
3. Marin MC, Kaelin WG Jr. p63 and p73: Old members of a new family. Biochim Biophys Acta 2000; 1470: 93-100.
4. Brunner HG, Hamel BC, Van Bokhoven H. The p63 gene in EEC and other syndromes. J Med Genet 2002; 39: 377-81.
5. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/ p63/p73 family of transcription factors: Overlapping and distinct functions. J Cell Sci 2000; 113: 1661-70.
6. Di Como CJ, Urist MJ. Babayan et al. p63 expression profiles human normal tumor tissues. Clin Cancer Res 2002; 8: 494-501.
7. Hall PA, Campbell SJ, O'Neill M et al. Expression of the p53 homologue p63alpha and deltaNp63alpha in normal and neoplastic cells. Carcinogenesis 2000; 21: 153-60.
8. Nylander K, Vojtesek B, Nenutil R et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002; 198: 417-27.
9. Pruneri G, Fabris S, Dell'orto P et al. The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. J Pathol 2005 July; 206 (3): 337-45.
10. Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. WHO Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001.
11. Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000; 24: 846-52.
12. Chang CC, Ye BH, Chaganti RS, Dalla-Favera R. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci USA 1996; 93: 6947-52.
13. Pasqualucci L, Bereschenko O, Niu H et al. Molecular pathogenesis of non-Hodgkin's lymphoma: The role of Bcl-6. Leuk Lymphoma 2003; 44 (Suppl. 3): 5-12.
14. Ree HJ, Yang WI, Kim CW et al. Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: Significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma. Hum Pathol 2001; 32: 954-62.
15. Ree HJ, Ohshima K, Aozasa K et al. Detection of germinal center B-cell lymphoma in archival specimens: Critical evaluation of Bcl-6 protein expression in diffuse large B-cell lymphoma of the tonsil. Hum Pathol 2003; 34: 610-6.
16. Feline B, Biscotti M, Puckering A et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95: 2084-92.
17. Natkunam Y, Warnke RA, Montgomery K, Falini B, van De Rijn M. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol 2001; 14: 686-94.
18. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
19. Colomo L, Lopez-Guillermo A, Perales M et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78-84.
20. Montoto S, Lopez-Guillermo A, Colomer D et al. Incidence and clinical significance of Bcl-2/Igh rearrangements in follicular lymphoma. Leuk Lymphoma 2003; 44: 71-6.
21. Lopez-Guillermo A, Cabanillas F, McDonnell TI et al. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphomas. Blood 1999; 93: 3081-7.
22. Huang JZ, Sanger WG, Greiner TC et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99: 2285-90.
23. Rosenwald A, Wright G, Chan WC et al. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-47.
24. Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-65.
25. Mirza I, Macpherson N, Paproski S et al. Primary cutaneous follicular lymphoma: An assessment of clinical, histopathologic, immunophenotypic, and molecular features. J Clin Oncol; 20: 647-55.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
27. MacPartlin M, Zeng S, Lee H. et al. p300 regulates p63 transcriptional activity. J Biol Chem 2005; 280: 30604-10.
28. Zigeuner R, Tsybrovskyy O, Ratschek M, Rehak P, Lipsky K, Langner C. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology 2004; 63: 1079-83.
29. Massion PP, Taflan PM, Jamshedur Rahman SM et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 2003; 63: 7113-21.
30. Hedvat CV, Teruya-Feldstein J, Puig P et al. Expression of p63 in diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol 2005; 13: 237-42.